Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 16/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20899645 | 0.84 | MEN1 (0.65) | L3MBTL1PTGS2 | |
| SCHEMBL2716691 | 0.76 | L3MBTL1 (0.70) | L3MBTL1 | |
| SCHEMBL23110876 | 0.76 | PTGS2 (0.68) | PTGS2 | |
| SCHEMBL24334901 | 0.76 | PTGS2 (0.68) | L3MBTL1PTGS2 | |
| SCHEMBL456924 | 0.75 | L3MBTL1 (0.69) | L3MBTL1 | |
| SCHEMBL8322277 | 0.75 | L3MBTL1 (0.69) | L3MBTL1 | |
| SCHEMBL8782898 | 0.75 | L3MBTL1 (0.69) | L3MBTL1 | |
| SCHEMBL23110602 | 0.75 | PTGS2 (0.63) | PTGS2 | |
| SCHEMBL14849565 | 0.74 | MAPT (0.63) | L3MBTL1 | |
| SCHEMBL24036413 | 0.74 | MEN1 (0.43) | L3MBTL1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | PMV PHARMACEUTICALS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2025-10-16 | — | — | US | disclosed |
| US-12419880-B2 | Companion diagnostic tool for mutant p53 reactivating compounds | PMV PHARMACEUTICALS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20240269126-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-11938124-B2 | Combination therapy for treatment of cancer | PMV PHARMACEUTICALS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230049952-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230044826-A1 | COMPANION DIAGNOSTIC TOOL FOR MUTANT P53 REACTIVATING COMPOUNDS | PMV PHARMACEUTICALS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20230033324-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20230024905-A1 | USES OF P53 X-RAY CO-CRYSTAL STRUCTURES | PMV PHARMACEUTICALS, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11938124-B2 | Combination therapy for treatment of cancer | TP53, KRAS, TP53BP1 | L3MBTL1 244/4885PTGS2 2934/4885 |
| US-20230049952-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | TP53, TP53BP1, KRAS | L3MBTL1 183/4885PTGS2 2729/4885 |
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | TP53, TP53BP1, KRAS | L3MBTL1 163/4885PTGS2 2539/4885 |
| US-20230033324-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | TP53, KRAS, TP53BP1 | L3MBTL1 244/4885PTGS2 2934/4885 |
| US-20230044826-A1 | COMPANION DIAGNOSTIC TOOL FOR MUTANT P53 REACTIVATING COMPOUNDS | TP53, TP53BP1, KRAS | L3MBTL1 191/4885PTGS2 4412/4885 |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, BRCA1 | L3MBTL1 180/4885PTGS2 1923/4885 |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | TP53, TP53BP1, ERCC2 | L3MBTL1 443/4885PTGS2 4360/4885 |
| US-20240269126-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | TP53, KRAS, TP53BP1 | L3MBTL1 244/4885PTGS2 2934/4885 |
| US-20230024905-A1 | USES OF P53 X-RAY CO-CRYSTAL STRUCTURES | TP53, TP53BP1, MDM2 | L3MBTL1 373/4885PTGS2 3427/4885 |
| US-12419880-B2 | Companion diagnostic tool for mutant p53 reactivating compounds | TP53, TP53BP1, KRAS | L3MBTL1 191/4885PTGS2 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.